Cardiac Magnetic Resonance Spectroscopic Correlates of Cardiac Sympathetic Denervation in Parkinson’s disease: A Comparison with MSA-P and Healthy Controls

Not Applicable

Recruiting

• Conditions: G20; G90.3; Parkinson disease

• Registration Number: DRKS00006061
• Lead Sponsor: Abteilung für Neurobiologie, Department für Neurologie, Medizinische Universität Innsbruck

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

PD Patients:
•Clinical diagnosis of PD according to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria (Hughes, Ben-Shlomo et al. 1992)

•Current age between 30 – 90 years
•The subject must be able to give written informed consent (full contractual capability)
•The subject must be willing to participate in all study related activities and visits

MSA Patients:
•Clinical diagnosis of probable MSA-P according to the revised Gilman criteria (Gilman, Wenning et al. 2008)
•Current age between 30 – 90 years
•The subject must be able to give written informed consent (full contractual capability)
•The subject must be willing to participate in all study related activities and visits

Healthy volunteers:
•Current age between 30 – 90 years
•The subject must be able to give written informed consent (full contractual capability)
•The subject must be willing to participate in all study related activities and visits

Exclusion Criteria

•History of other major neurological or psychiatric disorders or conditions
•History of coronary heart disease, ischemic and non-ischemic cardiomyopathy
•Heart failure determined by echocardiography (ejection fraction below reference range)
•Cardiac denervation unrelated to parkinsonism (e.g. diabetic neuropathy or heart transplantation as determined by history or laboratory findings [i.e. HbA1c])
•Known or suspected pregnancy or breastfeeding
•Presence of contraindication to MRI (e.g. implants)
•Dependence on any drug that intereferes with MIBG

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnostic value of cardiac magnetic resonance spectroscopy profiles in differentiating PD, MSA and healthy controls

Secondary Outcome Measures

Name	Time	Method
Correlation of imaging read-outs with cardiovascular autonomic measures